IPO Issue Details
Issue Price / Price Band₹34 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size4,000 Shares per Lot
Total Issue Size31,00,000 shares (aggregating up to ₹10.54 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital
Exchange / PlatformNSE SME
IPO TypeSME
Subscription OpenFri, 21 Jun 2024
Subscription CloseTue, 25 Jun 2024
Anchor AllotmentThu, 20 Jun 2024
Basis of AllotmentWed, 26 Jun 2024
Initiation of RefundsThu, 27 Jun 2024
Credit of Shares to DematThu, 27 Jun 2024
Listing DateFri, 28 Jun 2024
UPI Mandate Deadline2024-06-25
Application & Investment Details
Retail — Min (1 Lots)₹1,36,000 — 4,000 shares
Retail — Max (13 Lots)₹1,768,000 (13 Lots)
HNI — Min (2 Lots)₹2,72,000 — 8,000 shares
EPS (Pre-IPO)₹1.11
EPS (Post-IPO)₹2.21
P/E Ratio (Pre-IPO)30.53x
P/E Ratio (Post-IPO)15.41x
Net Offer to Public29,28,000 shares (aggregating up to ₹9.96 Cr)
Reserved for Market Maker1,72,000 shares (aggregating up to ₹0.5848 Cr)
Pre-IPO Promoter Holding86,00,000 shares
Post-IPO Promoter Holding1,17,00,000 shares
About Medicamen Organics Ltd
Medicamen Organics Limited was incorporated in 1995 and develops, manufactures, and distributes pharmaceutical dosages including generic dosages in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions and dry powders for the Government (including State Governments and Central Governments) and private entities as a contract manufacturer/third party manufacturer.The company's product list comprises 84 products and offers a wide range of drugs such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral and non-steroidal anti-inflammatory drugs (NSAIDS).The company's products are marketed throughout India as well as in African, CIS, and South East Asian countries such as Congo, Benin, Kameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya through third-party distributors.The company has two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, covering an area of 21,536 Sq. Ft. As on September 30, 2023, the company has entered into contract manufacturing with 38 domestic partners and 12 merchant exporters.As of September 30, 2023, the company employed a total of 116 people.
Objects of the Issue
Medicamen Organics Ltd proposes to utilise the net proceeds from the Issue for the following objects:
1
Funding of expenses proposed to be incurred towards Product registration in the international markets;
2
Plant updation and increase in production capacity;
3
Funding working capital requirements of our Company; and
4
General Corporate Purposes.
Shareholding & Lock-in
Pre-IPO Promoter Holding
86,00,000 shares
Post-IPO Promoter Holding
1,17,00,000 shares